Half of the animals subsequently received a two-week dose of a genetically designed, HIV-specific poison, or immunotoxin
, to complement the antiretrovirals, while the other half continued receiving antiretrovirals alone.
Additionally, multiple INDs are expected in the next 12-24 months resulting from preclinical and discovery work underway to advance multiple antibody, immunotoxin
, and protein decoy candidates, systemic delivery and a next generation RheoSwitch Therapeutic System(R).
At the National Eye Institute in collaboration with the National Cancer Institute, an immunotoxin
was developed and employed in the murine PIOL model.
United States Department of Health and Human Services (Washington, DC) has patented recombinant immunotoxin
fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins.
Phase I trial of recombinant immunotoxin
RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
National Cancer Institute (NCI), "NCI Researchers Develop Modified Immunotoxin
for Cancer Therapy in Mouse Study", December 4, 2006
Researchers in the neurosciences, psychology, pharmaceuticals, and other specialties introduce the considerations and background of the toxins, then describe examples of using the immunotoxin
192 IgG-saporin to make lesions on the cholinergic basal forebrain, the anti-DBH-saporin to make remarkably selective lesions of catecholaminergic neurons, hypocretin-saporin to produce narcoleptic animals, a variety of saporin conjugates in pain research, and cholera toxin B chain- saporin to produce a model of CNS dymyelination.
These activated T cells are then eliminated with an immunotoxin
against the cellular activation marker, CD25.
review that features ONCONASE will appear in "Handbook of Therapeutic Antibodies" (Wiley-VCH, Weinheim, Germany: Volume 3), edited by Professor Stefan Dubel from the Technical University of Braunschweig (Braunschweig, Germany).
This has stalled the field a great deal," says immunotoxin
investigator Daniel A.
GCR-3888 is an immunotoxin
fusion protein between a murine anti-CD22 disulphide-linked Fv antibody fragment (dsFv) and the Pseudomonas exotoxin PE38, and GCR-8015 is an optimized version of GCR-3888 with increased affinity for CD22.
has assumed worldwide rights to develop and market LMB-9, a recombinant immunotoxin
which was designed as a treatment for a wide variety of cancers.